There is only one sure way to judge individuals. Those with proven track record of knowledge and are open to sharing and helping (Mike & PB for example) can be easily judged and their comments are taken seriously and often times eagerly awaited. Then you have the idiots that pop from nowhere spewing sub-intellectual thoughts like you know who. Luckily I only get to see the first comment such idiots make because I never get to waste time on reading garbage. I IGNORE them and I am left only with the good people to enjoy reading what they share with the board.
regardless, gemuese, why would you have a "Long-Term Sentiment Disclosure" as a "strong sell" if you acknowledge that institutions "may flood in in a while?" That post flag has a "strong smell" to it.
Admittedly the way Yahoo has it defined, it is never a short term sentiment and therefore it is biased toward flagging "buy" and "strong buy" unless you are a dying industry such as a big box retailer or like what happened to Blockbuster Video years ago. Those would be legitimate strong sells before their decline.
Anyway, there is no such thing as a long term sentiment of "strong sell" for an under-valued game-changing biotech with a demonstrably successful technology that will be a first-mover into a virgin market in a couple of years.
Only a tard would flag it as such.
Sentiment: Strong Buy
certainly, if it wasn't a huge home run - they would have just let it go ---
Yes, sorry if I sounded negative Claude...they have had a great turnaround and it is still going!
I have been burned on miners though so I am not going too deep in any of them. If it goes up another buck I will be happy with my extra $25,000.
Only this may not be capitulation yet. If IBB breaks through support at 334, then, with the help of the shorts, we could actually see MNKD testing $3.75 support. If so I will double my position.
LOL, I would say that any school would be proud to admit that you are a graduate after reading this gem
"My business knowledge far exceeds yours! Again I have a Degree! Just to late everyone know your a liar and make up stupid stuff"
It's like they are little trick-or-treaters getting a candy pop corn ball for the first time.. LOL I laugh every single time we go thru a little hic-up like this and than recover. And these little nubs pop out singing & dancing for just a short while.. It's just way to to funny!..............HahahhahahahaBOOM!
Sentiment: Strong Buy
I can't find a lower day in years.
LMAO so true, my friend
Sentiment: Strong Sell
There are actually a number of other 100% HOCl products on the market with extensive shelf life. Some up to 5 years shelf life. So please, speak with fact. And in that spirit, here's the potential downside according to one of NBY's analysts:
Avenova is NovaBay’s first product. The company has never marketed a product and has a new, untested sales force. Adoption patterns are an unknown among the target prescribers. NovaBay is highly dependent on Avenova’s marketing success. Avenova is a prescription product dispensed by doctors and pharmacies, but is not reimbursable by third-party payers. The $30-$40 per month price may slow market penetration and sales.
Although Avenova may be effective and convenient, it may not get the continuous use as a preventive or the
market penetration expected. While it may be a good choice for those patients with severe inflammation, the moderately affected market may be difficult to penetrate. Avenova improves hygiene and eliminates bacteria, but is not the only product for these conditions, and the majority of the market will pursue OTC remedies, such as soaps, surfactant-based lid scrubs, antibiotics, steroids, and warm compresses before seeking out
Although the company’s products have a proprietary formulation, competitors may be able to develop products that also clean away bacteria without irritation. One of the more serious symptoms resulting from eyelid infection is the evaporation of tears and the dry eye that results. Newer artificial tear products have been introduced to include ingredients to prevent tears from evaporating. Competitors could add an anti-infective agent to control bacteria at the edge of the eyelid and the infection that results. This could reduce the patient population of eyelid
infection patients and/or take market share.
I agree, you have made my point, there is no swap in MILL's future for pferred for common, and no hope for MILL in any way, they are as Mac would say...#$%$ up! As, most likely, is your employment! You can defend this loser as much as you want, but in the end they are gone, history, Bk etc etc etc. And you will move on to the next promotional scheme in your line of work. But just maybe, I will be there and point out your past results! Oh yeah, it was me who asked the SEC to look at your posts with an eye to mislead stake holders because of your potential for having inside information. Have a good day, maybe one of your last????
I added more today. I trade this stock on a monthly basis. At some point soon, the stock price is going to go higher and at that time I will be in a holding pattern. Current cost basis is $3.11 and will continue to add towards the xdate. Accumulating at today's prices is a no brainer.